A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen
Study of CTX-009 Alone or in Combination with Paclitaxel in Patients with Cancer
Sponsor: Compass Therapeutics, Inc
Enrolling: Male and Female Patients
IRB Number: AAAU8625
U.S. Govt. ID: NCT05506943
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done and paid for by Compass Therapeutics (Compass), a company that does drug research studies in order to develop new drugs. Compass is studying a drug called CTX-009. This is an experimental drug being developed to potentially stimulate the immune system to fight against cancer (called, the study drug). Experimental means that the study drug is currently being tested and is not approved for sale in the United States by the Food and Drug Administration (FDA) or by any other regulatory authority in any other country. This study will also use paclitaxel, which is a chemotherapy drug. The main purpose of this study is to compare the effects of using study drug along with the chemotherapy paclitaxel to using paclitaxel alone. This study will allow the researchers to know whether this different treatment is better, the same, or worse at shrinking tumors.
Do You Qualify?
Are you at least 18 years old? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator